Maze Therapeutics, Inc. MAZE

Annual Quarterly

No annual revenue total was found in MAZE THERAPEUTICS, INC.'s SEC filings.

Maze Therapeutics, Inc. (MAZE) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$112.7 million. As of Jun 30, 2026 it held $494.9 million in cash and investments and $60.4 million in total debt.

Revenue (TTM)
$187.50M
Net income (TTM)
$-133.59M
Operating cash flow (TTM)
$-106.54M
Free cash flow (TTM)
$-106.84M
EPS (TTM)
$-2.52
Dividend per share
None
Shares outstanding
49.34M
Net cash
$434.49M
as of Jun 30, 2026
Operating margin
-77.7%
FY 2026

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
MAZE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
, Emerging growth company
SEC CIK
1842295

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Operating income
-$142.9M
Net income
-$131.1M
Diluted EPS
-$3.05
Operating cash flow
-$111.9M
Free cash flow
-$112.7M
Total assets
$397.1M
Total liabilities
$42.2M
Stockholders' equity
$355.0M
Cash and investments
$360.0M
Total debt
$23.3M

Recent SEC filings

Form Description Filed Period
8-K Current report
Material agreement, Unregistered share sale
 Oct 16, 2026 Oct 15, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
 Aug 17, 2026 Aug 13, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 11, 2026 Aug 11, 2026
8-K Current report
Shareholder vote results
 Jun 10, 2026 Jun 8, 2026
8-K Current report
Officer or director change
 May 22, 2026 May 18, 2026

All 222 Maze Therapeutics, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.